In other muscle disorders due to defects in the lipid metabolism, such as very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD), trifunctional protein deficiency (TFP), and carnitine palmitoyl transferase II deficiency (CPT II), medium-branched chain fatty acids were successfully utilized as anaplerotic treatments. The gene discussed is CPT2; the disease is very long chain acyl-CoA dehydrogenase deficiency.